Company news

PolyPid Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

January 29, 2025

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

January 28, 2025

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

December 23, 2024

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

December 10, 2024

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance

November 28, 2024

PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 12, 2024

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

November 6, 2024

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

October 29, 2024

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

October 20, 2024

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

September 30, 2024

PolyPid to Participate in Three Upcoming Fall Investor Conferences

September 2, 2024

PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 13, 2024

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

August 1, 2024

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

July 30, 2024

PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial

June 17, 2024

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial

June 9, 2024

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 7, 2024

PolyPid to Participate in Citizens JMP Life Sciences Conference

April 30, 2024

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

April 29, 2024

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

April 23, 2024

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

February 27, 2024

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

February 13, 2024

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

February 11, 2024

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

January 30, 2024

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

January 3, 2024

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 7, 2023

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

November 6, 2023

PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

October 31, 2023

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

October 10, 2023

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

October 8, 2023

PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

October 3, 2023

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 21, 2023

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

September 20, 2023

PolyPid Announces Reverse Share Split

September 19, 2023

PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀

September 18, 2023

PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 8, 2023

PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023

July 25, 2023

PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

June 28, 2023

PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

June 21, 2023

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

June 4, 2023

PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

May 21, 2023

PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 9, 2023

PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023

April 25, 2023

PolyPid to Participate in Upcoming Investor Conferences

April 23, 2023

PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds

March 30, 2023

PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants

March 28, 2023

PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares

March 27, 2023

PolyPid to Present at the Barclays Global Healthcare Conference

March 6, 2023

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

February 7, 2023

PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023

January 30, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.